Accordingly, EGFR TKI therapy (including erlotinib, gefitinib, and afatinib) has emerged as a first-line therapy for NSCLC patients with EGFR-activating mutations [14,15]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.